{"protocolSection": {"identificationModule": {"nctId": "NCT01383499", "orgStudyIdInfo": {"id": "205.425"}, "secondaryIdInfos": [{"id": "2010-022458-18", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Boehringer Ingelheim", "class": "INDUSTRY"}, "briefTitle": "A Study to Evaluate Efficacy and Safety of Tiotropium in Children 6 to 11 Years Old With Moderate Asthma", "officialTitle": "A Phase II Randomised, Double-blind, Placebo-controlled Incomplete Crossover Trial With 4-week Treatment Periods to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution (Doses of 1.25 \u00b5g, 2.5 \u00b5g and 5 \u00b5g) Delivered Via Respimat\u00ae Inhaler Once Daily in the Evening in Children 6 to 11 Yrs Old With Moderate Persistent Asthma"}, "statusModule": {"statusVerifiedDate": "2015-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2011-08"}, "primaryCompletionDateStruct": {"date": "2012-09", "type": "ACTUAL"}, "completionDateStruct": {"date": "2012-09", "type": "ACTUAL"}, "studyFirstSubmitDate": "2011-06-20", "studyFirstSubmitQcDate": "2011-06-27", "studyFirstPostDateStruct": {"date": "2011-06-28", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2013-09-23", "resultsFirstSubmitQcDate": "2013-12-04", "resultsFirstPostDateStruct": {"date": "2013-12-30", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-03-26", "lastUpdatePostDateStruct": {"date": "2015-04-15", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Boehringer Ingelheim", "class": "INDUSTRY"}, "collaborators": [{"name": "Pfizer", "class": "INDUSTRY"}]}, "descriptionModule": {"briefSummary": "The aim of this trial is to select an optimum dose may be selected based on bronchodilator efficacy, safety evaluations and pharmacokinetics of tiotropium bromide."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 101, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Treatment A", "type": "EXPERIMENTAL", "description": "patients inhale 2 puffs (low dose) once daily in the evening via Respimat inhaler", "interventionNames": ["Drug: Tiotropium bromide"]}, {"label": "Treatment B", "type": "EXPERIMENTAL", "description": "patients inhale 2 puffs (medium dose) once daily in the evening via Respimat inhaler", "interventionNames": ["Drug: Tiotropium bromide"]}, {"label": "Treatment C", "type": "EXPERIMENTAL", "description": "patients inhale 2 puffs (high dose) once daily in the evening via Respimat inhaler", "interventionNames": ["Drug: Tiotropium bromide"]}, {"label": "Treatment D", "type": "PLACEBO_COMPARATOR", "description": "patients inhale 2 puffs of placebo inhalation solution matching tiotropium once daily in the evening via Respimat inhaler", "interventionNames": ["Drug: Tiotropium bromide"]}], "interventions": [{"type": "DRUG", "name": "Tiotropium bromide", "description": "inhalation solution administered via Respimat in 3 different doses", "armGroupLabels": ["Treatment D"]}, {"type": "DRUG", "name": "Tiotropium bromide", "description": "inhalation solution administered via Respimat in 3 different doses", "armGroupLabels": ["Treatment C"]}, {"type": "DRUG", "name": "Tiotropium bromide", "description": "inhalation solution administered via Respimat in 3 different doses", "armGroupLabels": ["Treatment B"]}, {"type": "DRUG", "name": "Tiotropium bromide", "description": "inhalation solution administered via Respimat in 3 different doses", "armGroupLabels": ["Treatment A"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Forced Expiratory Volume (FEV1) Peak (0-3h) Response", "description": "The FEV1 peak (0-3h) response is determined at the end of the 4 week treatment period. This is the difference between the maximum FEV1 measured within the first 3 hours post dosing and the FEV1 baseline measurement. Analysis adjusted for treatment, period, patient and baseline using a mixed model.", "timeFrame": "Baseline and 4 weeks"}], "secondaryOutcomes": [{"measure": "Trough FEV1 Response", "description": "The trough FEV1 is defined as the pre-dose FEV1 measured just prior to the last administration of randomised treatment. Response was defined as the change from baseline. Analysis adjusted for treatment, period, patient and baseline using a mixed model.", "timeFrame": "Baseline and 4 weeks"}, {"measure": "Forced Vital Capacity (FVC) Peak (0-3h) Response", "description": "The FVC peak (0-3h) response is determined at the end of the 4 week treatment period. This is the difference between the maximum FVC measured within the first 3 hours post dosing and the FVC baseline measurement. Analysis adjusted for treatment, period, patient and baseline using a mixed model.", "timeFrame": "Baseline and 4 weeks"}, {"measure": "FVC Trough Response", "description": "The trough FVC response is defined as the pre-dose FVC measured just prior to the last administration of randomised treatment. Response was defined as the change from baseline. Analysis adjusted for treatment, period, patient and baseline using a mixed model.", "timeFrame": "Baseline and 4 weeks"}, {"measure": "FEV1 Area Under the Curve From 0 to 3 h (AUC0-3h) Response", "description": "FEV1 (AUC0-3h) will be calculated as the area under the curve from 0 to 3 hours using the trapezoidal rule divided by the observation time (3 hours) to report in litres. Response was defined as the change from baseline. Analysis adjusted for treatment, period, patient and baseline using a mixed model.", "timeFrame": "Baseline and 4 weeks"}, {"measure": "FVC Area Under the Curve From 0 to 3 h (AUC0-3h) Response", "description": "FVC (AUC0-3h) will be calculated as the area under the curve from 0 to 3 hours using the trapezoidal rule divided by the observation time (3 hours) to report in litres. Response was defined as the change from baseline. Analysis adjusted for treatment, period, patient and baseline using a mixed model.", "timeFrame": "Baseline and 4 weeks"}, {"measure": "Mean Morning Peak Expiratory Flow (PEF) Response", "description": "Mean morning PEF assessed by patients at home. Response was defined as the change from baseline. Analysis adjusted for treatment, period, patient and baseline using a mixed model.", "timeFrame": "Baseline and 4 weeks"}, {"measure": "Mean Evening PEF Response", "description": "Mean Evening PEF assessed by patients at home. Response was defined as the change from baseline. Analysis adjusted for treatment, period, patient and baseline using a mixed model.", "timeFrame": "Baseline and 4 weeks"}, {"measure": "Change From Baseline in the Number of Puffs of Rescue Medication Per Period (24 h, Daytime and Night-time Use)", "description": "Mean number of inhalations (puffs) of unscheduled rescue salbutamol therapy during whole day (24 h, daytime and night-time use). Analysis adjusted for treatment, period, patient and baseline using a mixed model.", "timeFrame": "Baseline and 4 weeks"}, {"measure": "Control of Asthma as Assessed by Asthma Control Questionnaire (ACQ)", "description": "ACQ is a questionnaire consisting of seven point Likert scale ranging from 0 to 6, whereby 0 represents good control and 6 represents poor control of asthma. The scale describes the frequency and severity of asthma symptoms. Analysis adjusted for treatment, period, patient and baseline using a mixed model.", "timeFrame": "4 weeks"}, {"measure": "Change From Baseline in Mean Number of Nighttime Awakenings", "description": "Mean number of nighttime awakenings due to asthma symptoms as assessed by patients eDiary incorporated in the AM3\u00ae device. Analysis adjusted for treatment, period, patient and baseline using a mixed model. The scores for this question used the following scale where: 1='Did not wake up', 2='Woke up once', 3='Woke up 2-5 times', 4='Woke up more than 5 times' and 5='Was awake all night'.", "timeFrame": "Baseline and last week of treatment (week 4)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion criteria:\n\nPatients must meet all of the following inclusion criteria to be eligible for enrollment into this study:\n\n1. All patients' parents (or legally accepted caregivers) must sign and date an informed consent prior to any study procedures including medication washout and restrictions. In addition, an informed assent suitable for this age group has to be obtained from patients.\n2. Male or female patients between 6 and 11 years of age (up to 1 day prior to their 12th birthday at Visit 1).\n3. All patients must have at least a 6-month history of asthma at the time of enrolment into the trial.\n4. All patients must have been on maintenance treatment with inhaled corticosteroids at a stable medium dose - a patient is eligible on =200 \u00b5g to =400 \u00b5g Budesonide DPI or equivalent.\n5. All patients must be symptomatic (partly controlled) at Visit 1 (screening) and prior to randomisation at Visit 2 as defined by an ACQ mean score of =1.5.\n6. All patients must have a pre-bronchodilator FEV1 =60% and =90% of predicted normal at Visit 1. Variation of absolute FEV1 values of Visit 2 (pre-dose) as compared to values at Visit 2 (pre-bronchodilator) must be within \u00b1 30%.\n7. All patients must demonstrate an increase in FEV1 of =12% 15 to 30 min. after 200 \u00b5g salbutamol (albuterol) at Visit 1.\n8. Patients must be able to inhale from the Respimat\u00ae inhaler correctly.\n9. Patients must be able to perform all trial related procedures including technically acceptable spirometric manoeuvres according to current ATS/ERS standards and the use of the electronic diary/peak flow meter.\n\nExclusion criteria:\n\nPatients with any of the following characteristics will not be eligible for entry into this study:\n\n1. Patients with a significant disease other than asthma.\n2. Patients with clinically relevant abnormal screening haematology or blood chemistry will be excluded if the abnormality defines a significant disease as defined in exclusion criterion 1. For participation in PK sampling, a haemoglobin of less than 11.3 g/dL will be regarded as exclusion criterion.\n3. Patients with a history of congenital or acquired heart disease, or patients who have been hospitalised for cardiac syncope or failure during the past year.\n4. Patients with any unstable or life-threatening cardiac arrhythmia, including cardiac arrhythmia requiring intervention (e.g. pacemaker implantation, catheter ablation etc.) or a change in drug therapy within the past year.\n5. Patients with a malignancy for which the patient has undergone resection, radiation therapy or chemotherapy within the last five years.\n6. Patients with clinically significant lung diseases other than asthma, such as CF, or bronchopulmonary dysplasia.\n7. Patients with known active tuberculosis.\n8. Patients who have undergone thoracotomy with pulmonary resection. Patients with a history of thoracotomy for other reasons should be evaluated as per exclusion criterion No. 1.\n9. Patients who are currently in a pulmonary rehabilitation program or have completed a pulmonary rehabilitation program in the 6 weeks prior to the screening visit (Visit 1).\n10. Patients with known hypersensitivity to anticholinergic drugs, BAC, EDTA or any other components of the tiotropium inhalation solution.\n11. Patients with known narrow-angle glaucoma, or any other disease where anticholinergic treatment is contraindicated.\n12. Patients with moderate to severe renal impairment, as defined by a creatinine clearance \\<50 mL/min./1.73 m2 BSA, as tiotropium is a predominantly renally excreted drug.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "6 Years", "maximumAge": "11 Years", "stdAges": ["CHILD"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Boehringer Ingelheim", "affiliation": "Boehringer Ingelheim", "role": "STUDY_CHAIR"}], "locations": [{"facility": "205.425.49005 Boehringer Ingelheim Investigational Site", "city": "Bochum", "country": "Germany", "geoPoint": {"lat": 51.48165, "lon": 7.21648}}, {"facility": "205.425.49004 Boehringer Ingelheim Investigational Site", "city": "Dresden", "country": "Germany", "geoPoint": {"lat": 51.05089, "lon": 13.73832}}, {"facility": "205.425.49002 Boehringer Ingelheim Investigational Site", "city": "Koblenz", "country": "Germany", "geoPoint": {"lat": 50.35357, "lon": 7.57883}}, {"facility": "205.425.36001 Boehringer Ingelheim Investigational Site", "city": "Budapest", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "205.425.36003 Boehringer Ingelheim Investigational Site", "city": "Budapest", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "205.425.36002 Boehringer Ingelheim Investigational Site", "city": "Mosdos", "country": "Hungary", "geoPoint": {"lat": 46.35379, "lon": 17.98853}}, {"facility": "205.425.36004 Boehringer Ingelheim Investigational Site", "city": "Szeged", "country": "Hungary", "geoPoint": {"lat": 46.253, "lon": 20.14824}}, {"facility": "205.425.37101 Boehringer Ingelheim Investigational Site", "city": "Baldone", "country": "Latvia", "geoPoint": {"lat": 56.74278, "lon": 24.39444}}, {"facility": "205.425.37105 Boehringer Ingelheim Investigational Site", "city": "Balvi", "country": "Latvia", "geoPoint": {"lat": 57.1313, "lon": 27.26583}}, {"facility": "205.425.37104 Boehringer Ingelheim Investigational Site", "city": "Daugavpils", "country": "Latvia", "geoPoint": {"lat": 55.88333, "lon": 26.53333}}, {"facility": "205.425.37106 Boehringer Ingelheim Investigational Site", "city": "Dubulti", "country": "Latvia", "geoPoint": {"lat": 56.96683, "lon": 23.76798}}, {"facility": "205.425.37102 Boehringer Ingelheim Investigational Site", "city": "Riga", "country": "Latvia", "geoPoint": {"lat": 56.946, "lon": 24.10589}}, {"facility": "205.425.37103 Boehringer Ingelheim Investigational Site", "city": "Riga", "country": "Latvia", "geoPoint": {"lat": 56.946, "lon": 24.10589}}, {"facility": "205.425.37004 Boehringer Ingelheim Investigational Site", "city": "Kaunas", "country": "Lithuania", "geoPoint": {"lat": 54.90272, "lon": 23.90961}}, {"facility": "205.425.37003 Boehringer Ingelheim Investigational Site", "city": "Taurage", "country": "Lithuania", "geoPoint": {"lat": 55.25222, "lon": 22.28972}}, {"facility": "205.425.37001 Boehringer Ingelheim Investigational Site", "city": "Vilnius", "country": "Lithuania", "geoPoint": {"lat": 54.68916, "lon": 25.2798}}, {"facility": "205.425.37002 Boehringer Ingelheim Investigational Site", "city": "Vilnius", "country": "Lithuania", "geoPoint": {"lat": 54.68916, "lon": 25.2798}}, {"facility": "205.425.07003 Boehringer Ingelheim Investigational Site", "city": "Moscow", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "205.425.07004 Boehringer Ingelheim Investigational Site", "city": "Moscow", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "205.425.07001 Boehringer Ingelheim Investigational Site", "city": "St. Petersburg", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "205.425.07002 Boehringer Ingelheim Investigational Site", "city": "St. Petersburg", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "205.425.38002 Boehringer Ingelheim Investigational Site", "city": "Donetsk", "country": "Ukraine", "geoPoint": {"lat": 48.023, "lon": 37.80224}}, {"facility": "205.425.38004 Boehringer Ingelheim Investigational Site", "city": "Kiev", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "205.425.38003 Boehringer Ingelheim Investigational Site", "city": "Zaporizhya", "country": "Ukraine", "geoPoint": {"lat": 50.60727, "lon": 31.78792}}]}, "referencesModule": {"references": [{"pmid": "25851298", "type": "DERIVED", "citation": "Vogelberg C, Moroni-Zentgraf P, Leonaviciute-Klimantaviciene M, Sigmund R, Hamelmann E, Engel M, Szefler S. A randomised dose-ranging study of tiotropium Respimat(R) in children with symptomatic asthma despite inhaled corticosteroids. Respir Res. 2015 Feb 7;16(1):20. doi: 10.1186/s12931-015-0175-9. Erratum In: Respir Res. 2015;16:128."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Tio R5/Placebo/Tio R1.25", "description": "Patients treated with Tiotropium 5 mcg in Period 1, with Placebo in Period 2 and with Tiotropium 1.25 mcg in Period 3. All products were administered once daily (QD) in the evening, delivered by the Respimat\u00ae inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication. No washouts (off treatment periods) between treatments."}, {"id": "FG001", "title": "Tio R1.25/Tio R5/Tio R2.5", "description": "Patients treated with Tiotropium 1.25 mcg in Period 1, with Tiotropium 5 mcg in Period 2 and with Tiotropium 2.5 mcg in Period 3. All products were administered once daily (QD) in the evening, delivered by the Respimat\u00ae inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication. No washouts (off treatment periods) between treatments."}, {"id": "FG002", "title": "Placebo/Tio R2.5/Tio R5", "description": "Patients treated with Placebo in Period 1, with Tiotropium 2.5 mcg in Period 2 and with Tiotropium 5 mcg in Period 3. All products were administered once daily (QD) in the evening, delivered by the Respimat\u00ae inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication. No washouts (off treatment periods) between treatments."}, {"id": "FG003", "title": "Tio R2.5/Tio R1.25/Placebo", "description": "Patients treated with Tiotropium 2.5 mcg in Period 1, with Tiotropium 1.25 mcg in Period 2 and with Placebo in Period 3. All products were administered once daily (QD) in the evening, delivered by the Respimat\u00ae inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication. No washouts (off treatment periods) between treatments."}], "periods": [{"title": "Period 1 (4 Weeks)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "27"}, {"groupId": "FG001", "numSubjects": "24"}, {"groupId": "FG002", "numSubjects": "25"}, {"groupId": "FG003", "numSubjects": "25"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "26"}, {"groupId": "FG001", "numSubjects": "24"}, {"groupId": "FG002", "numSubjects": "25"}, {"groupId": "FG003", "numSubjects": "25"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}, {"title": "Period 2 (4 Weeks)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "26"}, {"groupId": "FG001", "numSubjects": "24"}, {"groupId": "FG002", "numSubjects": "25"}, {"groupId": "FG003", "numSubjects": "25"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "26"}, {"groupId": "FG001", "numSubjects": "24"}, {"groupId": "FG002", "numSubjects": "25"}, {"groupId": "FG003", "numSubjects": "25"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}, {"title": "Period 3 (4 Weeks)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "26"}, {"groupId": "FG001", "numSubjects": "24"}, {"groupId": "FG002", "numSubjects": "25"}, {"groupId": "FG003", "numSubjects": "25"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "26"}, {"groupId": "FG001", "numSubjects": "24"}, {"groupId": "FG002", "numSubjects": "25"}, {"groupId": "FG003", "numSubjects": "25"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Total number of patients randomised and treated at all in the study.", "groups": [{"id": "BG000", "title": "Total.", "description": "Total number of patients randomised and treated at all in the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "101"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "8.8", "spread": "1.7"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "32"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "69"}]}]}]}, {"title": "Forced expiratory volume in 1s (FEV1)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Litre", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "1.640", "spread": "0.386"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Forced Expiratory Volume (FEV1) Peak (0-3h) Response", "description": "The FEV1 peak (0-3h) response is determined at the end of the 4 week treatment period. This is the difference between the maximum FEV1 measured within the first 3 hours post dosing and the FEV1 baseline measurement. Analysis adjusted for treatment, period, patient and baseline using a mixed model.", "populationDescription": "The Full analysis set (FAS) is defined as patients randomised, treated, with baseline data and at least one on-treatment efficacy measurement after 4 weeks on treatment within a period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Litre", "timeFrame": "Baseline and 4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo once daily (QD) in the evening delivered by the Respimat\u00ae inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication."}, {"id": "OG001", "title": "Tio R1.25", "description": "Tiotropium 1.25 microgram once daily (QD) in the evening delivered by the Respimat\u00ae inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication."}, {"id": "OG002", "title": "Tio R2.5", "description": "Tiotropium 2.5 microgram once daily (QD) in the evening delivered by the Respimat\u00ae inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication."}, {"id": "OG003", "title": "Tio R5", "description": "Tiotropium 5 microgram once daily (QD) in the evening delivered by the Respimat\u00ae inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "76"}, {"groupId": "OG001", "value": "75"}, {"groupId": "OG002", "value": "74"}, {"groupId": "OG003", "value": "75"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.185", "spread": "0.025"}, {"groupId": "OG001", "value": "0.261", "spread": "0.026"}, {"groupId": "OG002", "value": "0.290", "spread": "0.026"}, {"groupId": "OG003", "value": "0.272", "spread": "0.026"}]}]}], "analyses": [{"groupIds": ["OG000", "OG003"], "groupDescription": "Tio R5 minus Placebo", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0002", "pValueComment": "First step of closed testing procedure, where the active treatments are compared to placebo. If this statistical test significant at the 0.05 alpha level then proceed to comparison of the next lower dose to placebo.", "statisticalMethod": "Mixed model repeated measures (MMRM)", "statisticalComment": "This MMRM model includes treatment, period and baseline as fixed effects, and patient as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.087", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.042", "ciUpperLimit": "0.132", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.023"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Tio R2.5 minus Placebo", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<.0001", "pValueComment": "Second step of closed testing procedure. If this statistical test significant at the 0.05 alpha level then proceed to comparison of the next lower dose to placebo.", "statisticalMethod": "Mixed model repeated measures (MMRM)", "statisticalComment": "This MMRM model includes treatment, period and baseline as fixed effects, and patient as random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.104", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.059", "ciUpperLimit": "0.149", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.023"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Tio R1.25 minus Placebo", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0011", "statisticalMethod": "Mixed model repeated measures (MMRM)", "statisticalComment": "This MMRM model includes treatment, period and baseline as fixed effects, and patient as a random effect.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.075", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.030", "ciUpperLimit": "0.120", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.023"}, {"groupIds": ["OG001", "OG003"], "groupDescription": "Tio R5 minus Tio R1.25", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "statisticalMethod": "Mixed model repeated measures (MMRM)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.012", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.034", "ciUpperLimit": "0.057", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.023"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "Tio R5 minus Tio R2.5", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "statisticalMethod": "Mixed model repeated measures (MMRM)", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.017", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.063", "ciUpperLimit": "0.028", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.023"}, {"groupIds": ["OG001", "OG002"], "groupDescription": "Tio R2.5 minus Tio R1.25", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "statisticalMethod": "Mixed models repeated measures (MMRM)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.029", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.016", "ciUpperLimit": "0.074", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.023"}]}, {"type": "SECONDARY", "title": "Trough FEV1 Response", "description": "The trough FEV1 is defined as the pre-dose FEV1 measured just prior to the last administration of randomised treatment. Response was defined as the change from baseline. Analysis adjusted for treatment, period, patient and baseline using a mixed model.", "populationDescription": "FAS with at least one on-treatment value.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Litre", "timeFrame": "Baseline and 4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo once daily (QD) in the evening delivered by the Respimat\u00ae inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication."}, {"id": "OG001", "title": "Tio R1.25", "description": "Tiotropium 1.25 mcg once daily (QD) in the evening delivered by the Respimat\u00ae inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication."}, {"id": "OG002", "title": "Tio R2.5", "description": "Tiotropium 2.5 mcg once daily (QD) in the evening delivered by the Respimat\u00ae inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication."}, {"id": "OG003", "title": "Tio R5", "description": "Tiotropium 5 mcg once daily (QD) in the evening delivered by the Respimat\u00ae inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "76"}, {"groupId": "OG001", "value": "75"}, {"groupId": "OG002", "value": "74"}, {"groupId": "OG003", "value": "75"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.085", "spread": "0.026"}, {"groupId": "OG001", "value": "0.160", "spread": "0.026"}, {"groupId": "OG002", "value": "0.190", "spread": "0.026"}, {"groupId": "OG003", "value": "0.183", "spread": "0.026"}]}]}]}, {"type": "SECONDARY", "title": "Forced Vital Capacity (FVC) Peak (0-3h) Response", "description": "The FVC peak (0-3h) response is determined at the end of the 4 week treatment period. This is the difference between the maximum FVC measured within the first 3 hours post dosing and the FVC baseline measurement. Analysis adjusted for treatment, period, patient and baseline using a mixed model.", "populationDescription": "FAS with at least one on-treatment value.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Litre", "timeFrame": "Baseline and 4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo once daily (QD) in the evening delivered by the Respimat\u00ae inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication."}, {"id": "OG001", "title": "Tio R1.25", "description": "Tiotropium 1.25 mcg once daily (QD) in the evening delivered by the Respimat\u00ae inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication."}, {"id": "OG002", "title": "Tio R2.5", "description": "Tiotropium 2.5 mcg once daily (QD) in the evening delivered by the Respimat\u00ae inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication."}, {"id": "OG003", "title": "Tio R5", "description": "Tiotropium 5 mcg once daily (QD) in the evening delivered by the Respimat\u00ae inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "76"}, {"groupId": "OG001", "value": "75"}, {"groupId": "OG002", "value": "74"}, {"groupId": "OG003", "value": "75"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.202", "spread": "0.029"}, {"groupId": "OG001", "value": "0.208", "spread": "0.029"}, {"groupId": "OG002", "value": "0.253", "spread": "0.029"}, {"groupId": "OG003", "value": "0.239", "spread": "0.029"}]}]}]}, {"type": "SECONDARY", "title": "FVC Trough Response", "description": "The trough FVC response is defined as the pre-dose FVC measured just prior to the last administration of randomised treatment. Response was defined as the change from baseline. Analysis adjusted for treatment, period, patient and baseline using a mixed model.", "populationDescription": "FAS with at least one on-treatment value.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Litre", "timeFrame": "Baseline and 4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo once daily (QD) in the evening delivered by the Respimat\u00ae inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication."}, {"id": "OG001", "title": "Tio R1.25", "description": "Tiotropium 1.25 mcg once daily (QD) in the evening delivered by the Respimat\u00ae inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication."}, {"id": "OG002", "title": "Tio R2.5", "description": "Tiotropium 2.5 mcg once daily (QD) in the evening delivered by the Respimat\u00ae inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication."}, {"id": "OG003", "title": "Tio R5", "description": "Tiotropium 5 mcg once daily (QD) in the evening delivered by the Respimat\u00ae inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "76"}, {"groupId": "OG001", "value": "75"}, {"groupId": "OG002", "value": "74"}, {"groupId": "OG003", "value": "75"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.060", "spread": "0.030"}, {"groupId": "OG001", "value": "0.109", "spread": "0.030"}, {"groupId": "OG002", "value": "0.107", "spread": "0.030"}, {"groupId": "OG003", "value": "0.113", "spread": "0.030"}]}]}]}, {"type": "SECONDARY", "title": "FEV1 Area Under the Curve From 0 to 3 h (AUC0-3h) Response", "description": "FEV1 (AUC0-3h) will be calculated as the area under the curve from 0 to 3 hours using the trapezoidal rule divided by the observation time (3 hours) to report in litres. Response was defined as the change from baseline. Analysis adjusted for treatment, period, patient and baseline using a mixed model.", "populationDescription": "FAS with at least one on-treatment value.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Litre", "timeFrame": "Baseline and 4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo once daily (QD) in the evening delivered by the Respimat\u00ae inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication."}, {"id": "OG001", "title": "Tio R1.25", "description": "Tiotropium 1.25 mcg once daily (QD) in the evening delivered by the Respimat\u00ae inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication."}, {"id": "OG002", "title": "Tio R2.5", "description": "Tiotropium 2.5 mcg once daily (QD) in the evening delivered by the Respimat\u00ae inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication."}, {"id": "OG003", "title": "Tio R5", "description": "Tiotropium 5 mcg once daily (QD) in the evening delivered by the Respimat\u00ae inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "76"}, {"groupId": "OG001", "value": "75"}, {"groupId": "OG002", "value": "74"}, {"groupId": "OG003", "value": "75"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.110", "spread": "0.025"}, {"groupId": "OG001", "value": "0.178", "spread": "0.025"}, {"groupId": "OG002", "value": "0.208", "spread": "0.025"}, {"groupId": "OG003", "value": "0.201", "spread": "0.025"}]}]}]}, {"type": "SECONDARY", "title": "FVC Area Under the Curve From 0 to 3 h (AUC0-3h) Response", "description": "FVC (AUC0-3h) will be calculated as the area under the curve from 0 to 3 hours using the trapezoidal rule divided by the observation time (3 hours) to report in litres. Response was defined as the change from baseline. Analysis adjusted for treatment, period, patient and baseline using a mixed model.", "populationDescription": "FAS with at least one on-treatment value.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Litre", "timeFrame": "Baseline and 4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo once daily (QD) in the evening delivered by the Respimat\u00ae inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication."}, {"id": "OG001", "title": "Tio R1.25", "description": "Tiotropium 1.25 mcg once daily (QD) in the evening delivered by the Respimat\u00ae inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication."}, {"id": "OG002", "title": "Tio R2.5", "description": "Tiotropium 2.5 mcg once daily (QD) in the evening delivered by the Respimat\u00ae inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication."}, {"id": "OG003", "title": "Tio R5", "description": "Tiotropium 5 mcg once daily (QD) in the evening delivered by the Respimat\u00ae inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "76"}, {"groupId": "OG001", "value": "75"}, {"groupId": "OG002", "value": "74"}, {"groupId": "OG003", "value": "75"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.087", "spread": "0.027"}, {"groupId": "OG001", "value": "0.097", "spread": "0.027"}, {"groupId": "OG002", "value": "0.134", "spread": "0.027"}, {"groupId": "OG003", "value": "0.110", "spread": "0.027"}]}]}]}, {"type": "SECONDARY", "title": "Mean Morning Peak Expiratory Flow (PEF) Response", "description": "Mean morning PEF assessed by patients at home. Response was defined as the change from baseline. Analysis adjusted for treatment, period, patient and baseline using a mixed model.", "populationDescription": "FAS with at least one on-treatment value. For outcome measures obtained by AM3 device one patient in the \"TioR2.5\" group had no on-treatment data.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Litre/min", "timeFrame": "Baseline and 4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo once daily (QD) in the evening delivered by the Respimat\u00ae inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication."}, {"id": "OG001", "title": "Tio R1.25", "description": "Tiotropium 1.25 mcg once daily (QD) in the evening delivered by the Respimat\u00ae inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication."}, {"id": "OG002", "title": "Tio R2.5", "description": "Tiotropium 2.5 mcg once daily (QD) in the evening delivered by the Respimat\u00ae inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication."}, {"id": "OG003", "title": "Tio R5", "description": "Tiotropium 5 mcg once daily (QD) in the evening delivered by the Respimat\u00ae inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "76"}, {"groupId": "OG001", "value": "75"}, {"groupId": "OG002", "value": "73"}, {"groupId": "OG003", "value": "75"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.928", "spread": "5.103"}, {"groupId": "OG001", "value": "14.474", "spread": "5.127"}, {"groupId": "OG002", "value": "12.045", "spread": "5.177"}, {"groupId": "OG003", "value": "15.439", "spread": "5.127"}]}]}]}, {"type": "SECONDARY", "title": "Mean Evening PEF Response", "description": "Mean Evening PEF assessed by patients at home. Response was defined as the change from baseline. Analysis adjusted for treatment, period, patient and baseline using a mixed model.", "populationDescription": "FAS with at least one on-treatment value. For outcome measures obtained by AM3 device one patient in the \"TioR2.5\" group had no on-treatment data.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Litre/min", "timeFrame": "Baseline and 4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo once daily (QD) in the evening delivered by the Respimat\u00ae inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication."}, {"id": "OG001", "title": "Tio R1.25", "description": "Tiotropium 1.25 mcg once daily (QD) in the evening delivered by the Respimat\u00ae inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication."}, {"id": "OG002", "title": "Tio R2.5", "description": "Tiotropium 2.5 mcg once daily (QD) in the evening delivered by the Respimat\u00ae inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication."}, {"id": "OG003", "title": "Tio R5", "description": "Tiotropium 5 mcg once daily (QD) in the evening delivered by the Respimat\u00ae inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "76"}, {"groupId": "OG001", "value": "75"}, {"groupId": "OG002", "value": "73"}, {"groupId": "OG003", "value": "75"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.568", "spread": "5.081"}, {"groupId": "OG001", "value": "9.910", "spread": "5.103"}, {"groupId": "OG002", "value": "6.991", "spread": "5.150"}, {"groupId": "OG003", "value": "15.910", "spread": "5.103"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in the Number of Puffs of Rescue Medication Per Period (24 h, Daytime and Night-time Use)", "description": "Mean number of inhalations (puffs) of unscheduled rescue salbutamol therapy during whole day (24 h, daytime and night-time use). Analysis adjusted for treatment, period, patient and baseline using a mixed model.", "populationDescription": "FAS with at least one on-treatment value. For outcome measures obtained by AM3 device one patient in the \"TioR2.5\" group had no on-treatment data.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Puffs", "timeFrame": "Baseline and 4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo once daily (QD) in the evening delivered by the Respimat\u00ae inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication."}, {"id": "OG001", "title": "Tio R1.25", "description": "Tiotropium 1.25 mcg once daily (QD) in the evening delivered by the Respimat\u00ae inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication."}, {"id": "OG002", "title": "Tio R2.5", "description": "Tiotropium 2.5 mcg once daily (QD) in the evening delivered by the Respimat\u00ae inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication."}, {"id": "OG003", "title": "Tio R5", "description": "Tiotropium 5 mcg once daily (QD) in the evening delivered by the Respimat\u00ae inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "76"}, {"groupId": "OG001", "value": "75"}, {"groupId": "OG002", "value": "73"}, {"groupId": "OG003", "value": "75"}]}], "classes": [{"title": "24 h", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.664", "spread": "0.105"}, {"groupId": "OG001", "value": "-0.691", "spread": "0.105"}, {"groupId": "OG002", "value": "-0.314", "spread": "0.106"}, {"groupId": "OG003", "value": "-0.550", "spread": "0.105"}]}]}, {"title": "Daytime", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.338", "spread": "0.061"}, {"groupId": "OG001", "value": "-0.348", "spread": "0.062"}, {"groupId": "OG002", "value": "-0.130", "spread": "0.062"}, {"groupId": "OG003", "value": "-0.258", "spread": "0.062"}]}]}, {"title": "Night-time", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.354", "spread": "0.060"}, {"groupId": "OG001", "value": "-0.355", "spread": "0.060"}, {"groupId": "OG002", "value": "-0.180", "spread": "0.060"}, {"groupId": "OG003", "value": "-0.272", "spread": "0.060"}]}]}]}, {"type": "SECONDARY", "title": "Control of Asthma as Assessed by Asthma Control Questionnaire (ACQ)", "description": "ACQ is a questionnaire consisting of seven point Likert scale ranging from 0 to 6, whereby 0 represents good control and 6 represents poor control of asthma. The scale describes the frequency and severity of asthma symptoms. Analysis adjusted for treatment, period, patient and baseline using a mixed model.", "populationDescription": "FAS with at least one on-treatment value.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Score", "timeFrame": "4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo once daily (QD) in the evening delivered by the Respimat\u00ae inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication."}, {"id": "OG001", "title": "Tio R1.25", "description": "Tiotropium 1.25 mcg once daily (QD) in the evening delivered by the Respimat\u00ae inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication."}, {"id": "OG002", "title": "Tio R2.5", "description": "Tiotropium 2.5 mcg once daily (QD) in the evening delivered by the Respimat\u00ae inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication."}, {"id": "OG003", "title": "Tio R5", "description": "Tiotropium 5 mcg once daily (QD) in the evening delivered by the Respimat\u00ae inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "76"}, {"groupId": "OG001", "value": "75"}, {"groupId": "OG002", "value": "74"}, {"groupId": "OG003", "value": "75"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.966", "spread": "0.066"}, {"groupId": "OG001", "value": "0.909", "spread": "0.066"}, {"groupId": "OG002", "value": "0.846", "spread": "0.066"}, {"groupId": "OG003", "value": "0.879", "spread": "0.066"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Mean Number of Nighttime Awakenings", "description": "Mean number of nighttime awakenings due to asthma symptoms as assessed by patients eDiary incorporated in the AM3\u00ae device. Analysis adjusted for treatment, period, patient and baseline using a mixed model. The scores for this question used the following scale where: 1='Did not wake up', 2='Woke up once', 3='Woke up 2-5 times', 4='Woke up more than 5 times' and 5='Was awake all night'.", "populationDescription": "FAS with at least one on-treatment value. For outcome measures obtained by AM3 device one patient in the \"TioR2.5\" group had no on-treatment data.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "scores on a scale", "timeFrame": "Baseline and last week of treatment (week 4)", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo once daily (QD) in the evening delivered by the Respimat\u00ae inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication."}, {"id": "OG001", "title": "Tio R1.25", "description": "Tiotropium 1.25 mcg once daily (QD) in the evening delivered by the Respimat\u00ae inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication."}, {"id": "OG002", "title": "Tio R2.5", "description": "Tiotropium 2.5 mcg once daily (QD) in the evening delivered by the Respimat\u00ae inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication."}, {"id": "OG003", "title": "Tio R5", "description": "Tiotropium 5 mcg once daily (QD) in the evening delivered by the Respimat\u00ae inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "76"}, {"groupId": "OG001", "value": "75"}, {"groupId": "OG002", "value": "73"}, {"groupId": "OG003", "value": "75"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.135", "spread": "0.034"}, {"groupId": "OG001", "value": "-0.104", "spread": "0.034"}, {"groupId": "OG002", "value": "-0.080", "spread": "0.034"}, {"groupId": "OG003", "value": "-0.099", "spread": "0.034"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "4 weeks + 30 days if in last period.", "description": "All AEs, serious and non-serious, occurring during the course of the clinical trial were collected, documented, and reported to the sponsor by the investigator on the appropriate eCRF or SAE reporting forms.", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "Placebo once daily (QD) in the evening delivered by the Respimat\u00ae inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.", "seriousNumAffected": 0, "seriousNumAtRisk": 76, "otherNumAffected": 0, "otherNumAtRisk": 76}, {"id": "EG001", "title": "Tio R1.25", "description": "Tiotropium 1.25 microgram once daily (QD) in the evening delivered by the Respimat\u00ae inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.", "seriousNumAffected": 0, "seriousNumAtRisk": 75, "otherNumAffected": 0, "otherNumAtRisk": 75}, {"id": "EG002", "title": "Tio R2.5", "description": "Tiotropium 2.5 microgram once daily (QD) in the evening delivered by the Respimat\u00ae inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.", "seriousNumAffected": 0, "seriousNumAtRisk": 74, "otherNumAffected": 0, "otherNumAtRisk": 74}, {"id": "EG003", "title": "Tio R5", "description": "Tiotropium 5 microgram once daily (QD) in the evening delivered by the Respimat\u00ae inhaler, on top on maintenance therapy with an inhaled corticosteroid controller medication.", "seriousNumAffected": 0, "seriousNumAtRisk": 76, "otherNumAffected": 0, "otherNumAtRisk": 76}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract."}, "pointOfContact": {"title": "Boehringer Ingelheim Call Center", "organization": "Boehringer Ingelheim Pharmaceuticals", "email": "clintriage.rdg@boehringer-ingelheim.com", "phone": "1-800-243-0127"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000001965", "term": "Bromides"}, {"id": "D000069447", "term": "Tiotropium Bromide"}], "ancestors": [{"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000010276", "term": "Parasympatholytics"}, {"id": "D000018680", "term": "Cholinergic Antagonists"}, {"id": "D000018678", "term": "Cholinergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000000927", "term": "Anticonvulsants"}], "browseLeaves": [{"id": "M21860", "name": "Pharmaceutical Solutions", "relevance": "LOW"}, {"id": "M5241", "name": "Bromides", "asFound": "Root", "relevance": "HIGH"}, {"id": "M416", "name": "Tiotropium Bromide", "asFound": "Metabolites", "relevance": "HIGH"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M13189", "name": "Parasympatholytics", "relevance": "LOW"}, {"id": "M20760", "name": "Cholinergic Antagonists", "relevance": "LOW"}, {"id": "M20758", "name": "Cholinergic Agents", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}, {"id": "M4246", "name": "Anticonvulsants", "relevance": "LOW"}], "browseBranches": [{"abbrev": "PhSol", "name": "Pharmaceutical Solutions"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AntiConv", "name": "Anticonvulsants"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}]}}, "hasResults": true}